Deal read Read the calendar. The court ruling that put plaintiffs in an untenable position landed on 22 July. The settlement was announced on 27 July. The company states it is confident it would ultimately have prevailed, and its own record supports that. So the question is not whether J&J could have won, it is why a company winning chose to write a $5.5 billion cheque five days later. The answer is that litigation of this scale is unbounded in both time and outcome, and an unbounded liability cannot be modelled, financed or explained to a market. What the agreement does is convert it into a scheduled payable: a capped number, first instalment in 2027, nothing more before 2028, conditional on 95 percent participation so the tail cannot reopen. That is a company buying certainty at a price it can name, from a position of strength rather than exposure, which is the only position from which certainty is affordable. The timing has a second explanation worth watching. J&J is preparing to separate its Orthopaedics business, and no one carries 76,000 unresolved claims into a corporate separation of that size if they can help it.